Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin‐K antagonists: A retrospective German claims data analysis

Vitamin-K antagonists (VKAs) have widely been replaced by non-VKA oral anticoagulants (NOACs). This includes Austria, Germany and Switzerland, where as VKA, instead of warfarin, the much longer-acting phenprocoumon is used, which was not compared to NOACs in clinical trials.